sexta-feira, 13 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 27, 2026

Coca-Cola (KO) Ascends While Market Falls: Some Facts to Note

View original at finance.yahoo.com
Coca-Cola (KO) Ascends While Market Falls: Some Facts to Note Coca-Cola (KO) closed the most recent trading day at $75.71, moving +1.37% from the previous trading session…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Coca-Cola is predicted to post an EPS of $0.81, indicating a 10.96% growth compared to the equivalent quarter last year

    60% confidence
  • Changes in estimates have a direct relationship with upcoming stock price performance

    60% confidence
  • Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.31% increase

    60% confidence
  • For the entire fiscal year, revenue is predicted at $49.45 billion, indicating a change of +3.24% from the former year

    60% confidence
  • For the entire fiscal year, earnings are predicted at $3.24 per share, indicating a change of +8% from the former year

    60% confidence
  • Recent revisions to analyst estimates tend to reflect the evolving nature of short-term business trends, with upbeat changes indicating analysts' favorable outlook

    60% confidence
  • The Zacks Rank system has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988

    60% confidence
  • Coca-Cola's revenue is estimated at $12.32 billion, up 10.73% from the prior-year quarter

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Coca-Cola (KO) Ascends While Market Falls: Some Facts to Note — Source | Via News | pt.VIA.NEWS